PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: ZOLL Medical Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ZOLL LifeVest Wearable Defibrillator to be Showcased at European Society of Cardiology Heart Failure Congress 2015 - ZOLL® Medical Corporation announced that it will highlight the LifeVest® Wearable Defibrillator in Booth B80 at the European Society of Cardiology Heart Failure Congress 2015 from 23-26 May in Seville, Spain - ZOLL.com
ZOLL LifeVest Wearable Defibrillator to be Showcased at European Society of Cardiology Heart Failure Congress 2015

 

NewswireToday - /newswire/ - Chelmsford, MA, United States, 2015/05/22 - ZOLL® Medical Corporation announced that it will highlight the LifeVest® Wearable Defibrillator in Booth B80 at the European Society of Cardiology Heart Failure Congress 2015 from 23-26 May in Seville, Spain - ZOLL.com. NASDAQ: ZOLL

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will highlight the LifeVest® Wearable Defibrillator in Booth B80 at the European Society of Cardiology Heart Failure Congress 2015 from 23-26 May in Seville, Spain.

The LifeVest will be discussed during a symposium entitled “Preventing Sudden Cardiac Death in the Newly Diagnosed Heart Failure Patient,” chaired by Frank Ruschitzka, MD, University of Zurich, and John Morgan, MD, University of Southampton, and presented by Barry Greenberg, MD, University of California San Diego, and Stefan Winter, MD, St. Vinzenz Hospital, Cologne, Monday, 25 May, 12:45-1:45 pm., Rome Room.

In Europe, heart failure (HF) affects an estimated 15 million people, 1 and 3.6 million are newly diagnosed every year.2 Patients newly diagnosed with HF have a high mortality rate, up to 40% in the first year, including a high risk of sudden cardiac death (SCD).3 Compared to the general population, SCD occurs 6-9 times more frequently in HF patients, 4 and an acute event such as hospitalization for heart failure decompensation or myocardial infarction increases the SCD risk.5,6 Likewise, an HF patient’s condition can improve from the benefits of optimized medical therapy, which can require up to three months or more to stabilize.7

The LifeVest is worn by patients at risk for SCD, including patients with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest provides protection during their changing condition and while permanent SCD risk has not been established, allowing a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.

The LifeVest is lightweight and easy to wear, allowing patients to return to their common activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, and before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.

About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.

About Asahi Kasei
The Asahi Kasei Group (asahi-kasei.co.jp) is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.

1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
2. Facts and Figures: Heart Failure. European Society of Cardiology website. escardio.org/static_file/Escardio/Press-media/Facts-Figures-HF09.pdf. Accessed April 29, 2015.
3. O’Connor C, et al. Predictors of Mortality after Discharge in Patients Hospitalized with Heart Failure: An Analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Amer Heart J. 2008;156:662-73.
4. Rosamond W, et al. Heart Disease and Stroke Statistics 2008 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-46.
5. Adabag AS, Therneau TM, Gersh BJ, et al. Sudden Death after Myocardial Infarction. JAMA. 2008;300:2022-2029.
6. Solomon SD, Zelenkofske S, McMurray JV, et al. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. NEJM. 2005;352:2581-2588.
7. SA, et al. Time Course of Improvement in Left Ventricular Function, Mass and Geometry in Patients with Congestive Heart Failure Treated with Beta-adrenergic Blockade. JACC. 1995;25:1154-61.

Copyright © 2015 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are registered trademarks of ZOLL Medical Corporation in the United States and other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: ZOLL Medical Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


ZOLL LifeVest Wearable Defibrillator to be Showcased at European Society of Cardiology Heart Failure Congress 2015

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Diane Egan - ZOLL.com 
978-421-9637 degan[.]zoll.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ZOLL Medical Corporation securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From ZOLL Medical Corporation / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Intubation Market Significant Profits Estimated to be Generated by 2025 Says Persistence Market Research
PMR Releases Report for Next Generation IV Infusion Pumps Market Impact of Existing and Emerging Market 2017-2025
Medical Tapes Market to Reach US$ 2Bn by 2024 Reports PMR
Global Pyrogen Testing Market Value Expected to Increase to US$ 1.37 Billion by 2024 Says PMR
Huber Needles Market Expected to Reach US$ 55M by 2024 According to PMR
ZOLL Technologies for Improving CPR Quality to be Showcased at NTI 2017
ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men
Biomarker-based Technologies to Disrupt Conventional Diagnosis in Diabetes Management across the Globe Finds Frost & Sullivan
Agfa Specialty Products Announces the Launch of UNIQOAT
Sparta Releases Stratas 3.0 and TrackWise Intake
GE Healthcare Signs Agreement with HealthTrust to Supply Radiopharmaceuticals
GE Introduces CardioGraphe - The World’s First Dedicated Cardiovascular CT System
Frost & Sullivan Lauds ClearFlow’s ACT® Technology as a Transformational Force in Post-operative Cardiothoracic Surgery Protocols
ZOLL Receives Health Canada Approval for Two New Models of AEDS
ZOLL Hospital Wearable Defibrillator Receives Premarket Approval from the FDA

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)